Bafilomycin A1(Baf-A1)


Bafilomycin A1(Baf-A1)化学構造


Bafilomycin A1 is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM.

サイズ 価格(税別)  
JPY 49964.62


  • A549 cells and SK-1 cells co-treated with Baf A1 (100 nM) and SFN-NAC (30 μM) for 24 h, the expression of LC3 I and LC3 II was determined by Western blot.

    Cancer Lett, 2018, 431:85-95. Bafilomycin A1(Baf-A1) purchased from Selleck.

    HOS cells were pretreated with Baf-A1 (100 nM) for 2 h prior to treatment with CAP (100 μM) and DDP (16.7 μM) alone or in combination for 24 h. The expression levels of autophagy-related and apoptosis-related proteins were measured by Western blotting (a).

    J Exp Clin Cancer Res, 2018, 37(1):251. Bafilomycin A1(Baf-A1) purchased from Selleck.

  • Representative immunofluorescence images of TGF-β3-induced MUC5AC in 16HBE cells treated with 3-MA or Baf A1.

    EBioMedicine, 2018, 33:242-252. Bafilomycin A1(Baf-A1) purchased from Selleck.

    Expressions of LC3-I and LC3-II in protein were detected by Western blotting. Bafilomycin A1 significantly inhibited the effect of PNU282987 on LC3-II/I ratio in LPS-stimulated BV2 microglia (n = 6 per group).

    Front Immunol, 2017, 8:553. Bafilomycin A1(Baf-A1) purchased from Selleck.

  • HeLa cells were transfected with plasmid encoding Flag-IKKβ for 24 h. Before harvest, cells were treated with MG132 (10 μM), chloroquine (CQ, 50 μM), bafilomycin A1 (Baf A1, 100 nM), or 3-methyladenine (3-MA, 2.5 mM) for 8 h. Cell extracts were analyzed by immunoblotting. Numbers underneath the blot represent the fold change of Flag-IKKβ band intensity compared with control, using β-actin as a loading control.

    Front Immunol, 2018, 8:553. Bafilomycin A1(Baf-A1) purchased from Selleck.

    High glucose levels inhibit autophagic flux in cultured neonatal rat cardiomyocytes. c, Representative immunofluorescent NRCs expressing mRFP-GFP-LC3. *P < 0.05 vs. the autophagosomes in the corresponding group without bafilomycin A1 treatment; # P < 0.05 vs. the autolysosomes in the corresponding group without bafilomycin A1 treatment. Experiments were repeated four times. G5.5, glucose 5.5 mmol/L; G25, glucose 25 mmol/L; Ang II, angiotensin II; Baf, bafilomycin A1

    Cardiovasc Diabetol, 2016, 15(1):136.. Bafilomycin A1(Baf-A1) purchased from Selleck.

  • (B) U87-MG stable cell lines were serum starved for 24 h, then treated with EGF (50 ng/mL) along with DMSO (10 μM) or bafilomycin A1 (Baf-A1) (1 μM) or MG132 (10 μM) for 6 h. The lysates were subjected to western blot with the indicated antibodies. Densitometry quantification of T-EGFR/Tubulin protein levels was shown

    FEBS Lett, 2016, 590(9):1345-53. Bafilomycin A1(Baf-A1) purchased from Selleck.


Proton Pump阻害剤の選択性比較


製品説明 Bafilomycin A1 is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM.
H+-ATPase [1]
(Cell-free assay)
0.44 nM

Bafilomycin A1 is a toxic macrolide antibiotic derived from Streptomyces griseus. Bafilomycin A1 inhibits the short circuit current induced by the outer mantle epithelium (OME). The IC50 and maximum inhibition dose of Bafilomycin A1 are 0.17 μM and 0.5 μM, respectively. [2] In addition, Bilomycin A1 inhibits the acid influx with an IC50 value of 0.4 nM. Bafilomycin A1 inhibits the acidification dose-dependently resulting in a lower quenching, and thus a higher fluorescence. [3] Bafilomycin A1 prevents the vacuolization of Hela cells induced by H. pylori, with an inhibitory concentration giving 50% of maximal (ID50) of 4 nM. Bafilomycin A1 is also very efficient in restoring vacuolated cells to a normal appearance. [4] Bafilomycin A1 also affects the transport of endocytosed material from early to late endocytic compartments. Bafilomycin not only dissipates the low endosomal pH but also blocks transport from early to late endosomes in HeLa cells. [5] Bafilomycin A1 at doses of 0.1-1 μM completely inhibits the acidification of lysosomes revealed by the incubation with acridine orange in BNL CL.2 and A431 cells. [6] When Bafilomycin A1 is added to Hanks' balanced salt solution, endogenous protein degradation is strongly inhibited and numerous autophagosomes accumulated in H-4-II-E cells. Bafilomycin A1 also prevents the appearance of endocytosed HRP in autophagic vacuoles. [7]

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MCF7 cells Mli2SpVv[3Srb36gZZN{[Xl? MlqyOEBp MWnJcohq[mm2aX;uJI9nKHKjcHHtfYNqdi2rbnT1Z4VlKGG3dH;wbIFogSCrbjDoeY1idiCPQ1[3JINmdGy|IHX4dJJme3OrbnegSWdHWC2OQ{OgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iRVfGVEBt\X[nbIOgZZQhOTByIH7NJIFnfGW{IESgbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdicnXsZZRqfmVidH:gZ49vfHKxbB?= NUTLbGt4OjByMkixN|Q>
human HeLa cells NXT2XZF5TnWwY4Tpc44h[XO|YYm= MkXMOFAxKG6P MnfFTY5lfWO2aX;uJI9nKGG3dH;wbIFogSCrbjDoeY1idiCKZVzhJINmdGy|IHX4dJJme3OrbnegSWdHWC2OQ{OgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iTFOzMVIhdGW4ZXygZZQhPDByIH7N NIPYe3QyQDN7MUm0PS=>
mouse RAW264.7 cells M4X0S2Fxd3C2b4Ppd{Bie3OjeR?= M2DsZ|ExOCCwTR?= NUDkb3NpOTZiaB?= Mo\1TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDtc5V{\SCUQWeyOlQvPyClZXzsd{Bie3Onc4Pl[EBieyCuYYTlJIFxd3C2b4TpZ{Bk\WyuczDheEAyODBibl2gZYZ1\XJiMU[gbJJ{KHW|aX7nJIFvdmW6aX6gWk1xem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJ6KG[ub4egZ5l1d22ndIL5 NITpS2cyQTNyN{O1PS=>
RAW 264.7 cells NGTHUGFHfW6ldHnvckBie3OjeR?= MVuxNFAhdk1? NWq5dHRYSW62aX3pZ5Jw[mmjbDDhZ5Rqfmm2eTDh[4FqdnO2IGPhcI1wdmWubHGg[Y51\XKrY3GgWJlxcGmvdYLpeY0hOTRyMkigbY5n\WO2ZXSgbY4hWkGZIEK2OE44KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNm\CCwaYTybYMhd3irZHWgdJJw\HWldHnvckBqdiCrbn\lZ5Rm\CClZXzsd{BifCBzMECgcm0> M2S5dVE6OzB5M{W5
human H4 cells M2jjbGZ2dmO2aX;uJIF{e2G7 Mo\HNE41KM7:TR?= NGLvVmIzPCCq Mo\6TY5lfWO2aX;uJI9nKGyrZ3j0JINp[WmwIEOtS2ZRKGyndnXsJIlvKGi3bXHuJGg1KGOnbHzzJIF1KDBwNDD1UUBi\nSncjCyOEBpenNiYomgbIlocCC2aILveYdpeHW2IH\seY9z\XOlZX7j[UBucWO{b4Pjc5B6KHKnbHH0bZZmKHSxIHPvcpRzd2x? M3j4[lE5ODJ2NUi0


体内試験 Bafilomycin A1 (1 μM and 0.1 μM) completely inhibits the resorptive activity of cultured osteoclasts. [8] Bafilomycin A1 dose-dependently inhibits the rate of Na+ uptake in young tilapia with a Ki of 0.16 μM. [9]




+ 展開

ATPase enzyme activity assays:

The ATPase enzyme assay medium contains 6 mM MgSO4, 50 mM HEPES (pH 7.4), 200 mM Na2SO3 (V-ATPase activator), 0.5 mM sodium ortho-vanadate (P-ATPase inhibitor), 0.5 mM sodium azide (F-ATPase inhibitor) and 3 mM Na2ATP. This medium (1.0 mL), with or without the addition of the V-type ATPase inhibitor bafilomycin A1, is incubated with the filtered homogenate (0.1 mL) for 60 minutes at 23–25 °C. The reaction is stopped by the addition of 1 mL of TCA 3%. Spectrometric blanks are prepared as for the enzyme assay with the exception that the tissue sample is added after the acid. Phosphate analysis is accomplished by adding 2 mL of 1-butanol and 0.2 mL molybdate solution (5 g ammonium molybdate, 22 mL H2SO4 to 100 mL). After vortexing for 15 seconds the solution is neutralised with 0.5 mL citrate solution (100 g/500 mL, pH 7.0) and again vortexed for 15 seconds. The solution is then centrifuged (2000 × g; 3 minutes) to separate the butanol phase and the absorbance of this phase is read at 400 nm. Standards of orthophosphate are prepared (0.1 μM–2.0 μM) and treated in the same way as the enzyme activity assays. Enzyme activity is expressed in μmol of orthophosphate liberated per hour and per milligram of protein. V-ATPase activity is considered to be the difference between the total ATPase activity measured in the presence of Na2SO3, sodium orthovanadate and sodium azide and the ATPase activity measured in the presence of these reagents and of the specific V-ATPases inhibitor Bafilomycin A1.


+ 展開
  • 細胞株: HeLa cells
  • 濃度: ~20 nM
  • 反応時間: 20 hours
  • 実験の流れ:

    H. pylori bacteria extract is treated with inhibitors, before addition to HeLa cells, as follows: DCCD 10 mM for 1 hour at 30 ºC; NBD-CI 100 μM for 1 hour at 30 ºC and the reaction is blocked with glycine 10 mM final concentration; NEM 275 μM for 1 hour at 30 ºC and the reaction is blocked by addition of β-mercaptoethanol 275 mM; Mg-ATP 14 μM for 1 hour at 0 ºC; 100 μM KNO3 and 14 μM Mg-ATP for 1 hour at 30 μM; NaCO3 100 μM, pH 11 for 1 hour at 0 ºC. The bacterial extract is then added to cell with a 40-fold dilution at a final concentration of 0.65 mg/mL. Controls are HeLa cells incubated with untreated bacterial extracts and cells treated with inhibitor Bafilomycin A1 under the same conditions as bacterial extracts, at the same concentrations or after a 40-fold dilution. The vacuotating activity of the bacterial extracts is assayed.



+ 展開
  • 動物モデル: Young (approximately 9 days old) Mozambique tilapia, Oreochromis mossambicus
  • 製剤: Aquarium water containing 0.05 % dimethylsulphoxide (DMSO)
  • 投薬量: 10 μM
  • 投与方法: --

溶解度 (25°C)

体外 DMSO 6 mg/mL (9.63 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。


分子量 622.83


CAS No. 88899-55-2
in solvent
別名 N/A





質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)


  • 質量





開始濃度 x 開始体積 = 最終濃度 x 最終体積


この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1



  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):




チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2


質量 濃度 体積 分子量



Handling Instructions


  • * 必須


  • 質問1:

    How to dissolve it?

  • 回答:

    S1413 Bafilomycin A1(Baf-A1) is soluble in DMSO at 0.1 mg/ml. Please do not use alcohols as solvent, because this compound will degrade in alcohols.

Proton Pumpシグナル伝達経路

相関Proton Pump製品

Tags: Bafilomycin A1(Baf-A1)を買う | Bafilomycin A1(Baf-A1) ic50 | Bafilomycin A1(Baf-A1)供給者 | Bafilomycin A1(Baf-A1)を購入する | Bafilomycin A1(Baf-A1)費用 | Bafilomycin A1(Baf-A1)生産者 | オーダーBafilomycin A1(Baf-A1) | Bafilomycin A1(Baf-A1)化学構造 | Bafilomycin A1(Baf-A1)分子量 | Bafilomycin A1(Baf-A1)代理店
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID